Business Wire

Santen and IAPB Taking Action to Implement the First Ever UN General Assembly Resolution Recognizing the Link Between Eye Health and Sustainable Development

26.7.2021 10:00:00 EEST | Business Wire | Press release

Share

Santen Pharmaceutical Co., Ltd. (“Santen”) announced today that Santen, in partnership with the International Agency for the Prevention of Blindness (IAPB), will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health. This comes after several months of collaboration with the IAPB, advocating for global action to improve access to basic eye health services.

Santen is committed to reducing the loss of social and economic opportunities for people living with eye conditions. The new UN General Assembly resolution encourages governments and key stakeholders from around the world to mobilize the necessary resources to address this urgent priority. UN entities including UNICEF, UN-Women, UNDP, UNESCO, the International Labor Organization and the UN Road Safety Collaboration will work to promote and include eye health in their work. International financial institutions and donors will be urged to include eye health priorities in their funding programs. We take the adoption of this resolution as an opportunity to further enhance our policy and advocacy activities with the IAPB.

“The eye health sector has believed for a long time that quality eye care is critical to the world achieving the Sustainable Development Goals” said Peter Holland, CEO of IAPB. “IAPB and its members are committed to supporting governments to implement this resolution and ensure that no one is left behind”.

To support the implementation of this resolution, Santen and the IAPB will work together on a number of initiatives as part of their ongoing strategic partnership, including:

  • Partnership with national governments and supranational stakeholders to establish an effective monitoring system and encourage the inclusion of eye health in voluntary national reporting on the Sustainable Development Goals (SDGs).
  • Coordination of an advocacy and public affairs strategy to lobby for the inclusion of two eye health targets in the next review of the SDGs by the UN Inter-Agency Expert Group in 2025.

Today, 1.1 billion people are living with preventable sight loss due to a lack of access to basic eye care services. With appropriate allocation of resources and investment for the early detection and treatment of eye conditions, including disease awareness campaigns and regular eye tests, sight can be protected.1 Vision loss can have a significant detrimental impact on quality of life (QOL), including depression, discomfort and social isolation. Improving access to eye care services therefore, has the potential to improve the QOL for millions of people.2 Additionally, sight loss is calculated to cost the global economy $411bn in productivity each year, showing it has tremendous economic consequences3. Eye health is directly linked to more than half of the sustainable development goals (SDGs), including eliminating poverty and hunger, improving education, and gender equality4. Therefore, a “whole of government approach” to eye care and strengthened collaboration between stakeholders is necessary to ensure the people living with preventable sight loss receive access to support and treatment.

“The adoption of UN resolution on eye health represents a major leap towards the realization of our WORLD VISION (Happiness with Vision)” said Shigeo Taniuchi, President & CEO of Santen, “There is ample evidence that eye health is a global development issue. About 90% of preventable vision loss occurs in low and middle income countries, of which 55% affects women and girls. People, in general, receive 80% of information visually and eye disease tend to be chronic, affecting patients’ quality of life. As a specialized company dedicated to ophthalmology, we are committed to promoting international efforts on eye health and contributing to the realization of the SDGs. Supporting the implementation of this resolution is a crucial step towards facilitating access to eye care services and reducing the loss of social and economic opportunities for people around the world due to eye conditions”.

References:

  1. International Agency for the Prevention of Blindness (IAPB). Vision Atlas. Available here: https://www.iapb.org/learn/vision-atlas
  2. Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
  3. Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf
  4. Lancet Global Health Commission Report (2020). Available here: https://globaleyehealthcommission.org/app/uploads/2020/12/Commission-Report-1.pdf

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.
Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.
With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
For more information, please visit Santen’s website (www.santen.com).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate Communications Group
Santen Pharmaceutical Co., Ltd.
Takahiro Hidaka
E-mail: communication@santen.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release

Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo

Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release

Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release

GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for

Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye